Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc. is a biopharmaceutical company dedicated to the development of therapies aimed at genetically defined diseases. The primary focus of the company is on harnessing the power of gene regulation to treat rare genetic disorders by modulating expression of genes. Their approach leverages insights into the genetic and regulatory mechanisms to advance a robust pipeline of therapeutic candidates. Fulcrum’s key products target conditions such as fragile X syndrome and facioscapulohumeral muscular dystrophy, aiming to improve outcomes in areas with substantial unmet clinical needs. By addressing the root causes of diseases at the genetic level, Fulcrum Therapeutics plays a crucial role in the healthcare and pharmaceutical sectors, contributing significantly to precision medicine. The company’s pioneering work in epigenetic modulation positions it as a vital player in the biopharmaceutical industry, with ongoing research initiatives supporting its mission to transform the lives of patients with serious genetic conditions. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum Therapeutics combines scientific expertise with a commitment to innovation, driving forward therapies that can make a meaningful impact on patient health.